Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.CoMentis and Anvyl have agreed to form a joint venture (JV) referred to as Alpharmagen to advance the discovery and development of nicotinic modulators.
Subscribe to our email newsletter
The JV will focus on developing novel modulators of the alpha7 nicotinic acetylcholine receptor that is believed to play a vital role in cognition.
CoMentis president and CEO Terence Kelly said, "We believe that alpha7 modulators have the potential to become significant therapeutic agents, and we believe that the portfolio of allosteric modulators and the expertise that Anvyl brings provides a unique 2nd generation approach to the established alpha 7 agonist program that CoMentis has advanced."
Modulators of alpha7 nicotinic receptor in the human brain were proven to be useful in Phase II studies on cognitive disorders associated with schizophrenia and Alzheimer’s disease.
Anvyl chief operating officer David Putman said the teams can advance compounds quickly into clinical trials.